Agios Pharmaceuticals

Management took decisive portfolio steps: selling the oncology business to Servier (2021) and later monetizing vorasidenib U.S. royalties to Royalty Pharma (2024) to fund rare‑disease expansion without heavy dilution.

Recent BD to in‑license cevidoplenib diversifies into ITP, though the timeline to Phase 3 (targeted 2028) and prior Phase 2 nuances argue for measured investment. SBC is material but typical for the sector; share count growth has been moderate.

We view capital allocation as opportunistic and generally shareholder‑aware, with the main watch‑item being sustained opex versus revenue ramp while preserving the cash cushion.